Tissue-repair research asks how injured tissue rebuilds, one pathway at a time. Six Artemis compounds appear in that literature. This page explains the questions the field asks and the models it uses, then lists the research articles and the compounds.
Research Articles
What Is GHK-Cu Studied For? The Research Record | Artemis Labs
GHK-Cu is a copper-bound tripeptide. The main scientific database describes it as a cosmetic ingredient, and two human trials in 34 years were both…
Read article →ArticleGHK vs GHK-Cu: Two Different Molecules | Artemis Labs
GHK is CID 73587 at molecular weight 340.38. GHK-Cu is CID 71587328 at 402.92. Six PubChem records answer to the name GHK-Cu, and one…
Read article →ArticleGHK-Cu Wound Healing Research: The Full Evidence Record
The one human wound trial of GHK-Cu matched placebo. The animal record is split: rabbits and rats healed faster, guinea pigs healed slower. What…
Read article →ArticleGHK-Cu Topical vs Systemic Evidence: What Transfers | Artemis Labs
Most human GHK-Cu results come from multi-ingredient cosmetic products applied to skin. Here is why that evidence cannot be read across to research-vial material.
Read article →ArticleGHK-Cu Skin Research: What the Two Human Trials Found
GHK-Cu has two human randomized trials in 34 years. Both tested topical creams, and both were negative on every objective skin measurement. The full…
Read article →ArticleGHK-Cu Sequence and Identity: CID, CAS, Mass | Artemis Labs
The verified identifiers for both molecules: GHK at CID 73587, 340.38, CAS 49557-75-7, and GHK-Cu at CID 71587328, 402.92, CAS 89030-95-5.
Read article →ArticleGHK-Cu Safety Research: What Has and Has Not Been Measured | Artemis Labs
The copper-toxicity record for GHK-Cu is mixed and mostly reassuring in cell studies. It is also almost entirely silent, because no human has been…
Read article →ArticleGHK-Cu Human Trials: Two in 34 Years, Both Null | Artemis Labs
GHK-Cu has exactly two human randomized trials, published in 1992 and 2006. Both were topical, and both were negative on every objective endpoint measured.
Read article →ArticleGHK-Cu Hair Research: Every Study Is Multi-Ingredient
Every human hair study involving GHK or GHK-Cu tested a mixed formulation with other active ingredients. No single-agent human hair study is indexed in…
Read article →ArticleGHK-Cu Gene Expression: Where the Claims Come From
The expansive gene-expression claims about GHK trace to reviews sharing one company address. The only independent primary study is a 2012 computational screen.
Read article →ArticleGHK-Cu Copper Biology: What the Research Reports | Artemis Labs
What published work reports about the copper in GHK-Cu: bound copper versus free copper salts, the biphasic curve, and where the peptide may not…
Read article →ArticleHow to Read a Certificate of Analysis for GHK-Cu | Artemis Labs
What a GHK-Cu COA should show: sequence Gly-His-Lys, CID 71587328, 402.92 for the complex and 340.38 for the copper-free peptide.
Read article →ArticleGHK-Cu Anti-Inflammatory Research: What Studies Report | Artemis Labs
A plain-language review of the published GHK-Cu inflammation literature: which studies used cells, which used mice, which used zebrafish, and what each one found.
Read article →ArticleWhat Is TB-500 Studied For? Research Areas Explained
TB-500 is a seven-amino-acid fragment of thymosin beta-4. A plain-language tour of every research area the published record actually covers, and what it does…
Read article →ArticleTB-500 and Wound Research: What Human Skin Trials Found
The human skin-wound trials often linked to TB-500 tested thymosin beta-4, the larger parent protein. Here is what those studies reported, and what they…
Read article →ArticleIs TB-500 Banned by WADA? The 2026 List, Quoted
The 2026 WADA Prohibited List names Thymosin-beta4 and its derivatives e.g. TB-500 under section S2.3. Here is the quoted text, the source PDF, and…
Read article →ArticleTB-500 vs Thymosin Beta-4: Not the Same Molecule
TB-500 is a seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein about five times heavier. Here is what the published research actually tested.
Read article →ArticleTB-500 and Tissue Repair: What the Research Shows
TB-500 is a 7-amino-acid fragment of thymosin beta-4. Here is what repair research actually tested, which form it used, and what has never been…
Read article →ArticleTB-500 Sequence and Identity: The Analytical Facts
TB-500 is Ac-LKKTETQ-OH: seven amino acids, MW 889.0, CAS 885340-08-9. The verified identity numbers, plus the 847.0 free-acid mix-up worth avoiding.
Read article →ArticleTB-500 Safety Research: Published and Missing
What published research reports about TB-500 and thymosin beta-4 safety, including the one human safety study, the negative findings, and the gaps nobody has…
Read article →ArticleTB-500 Human Trials: What Exists and What Does Not
No human trial has ever tested TB-500 itself. The eleven human studies people cite all used thymosin beta-4, the larger parent protein. Here is…
Read article →ArticleTB-500 and Heart Research: The Human Trial
A randomized human trial of thymosin beta-4 after a heart attack was null overall, with a signal only in an early-dosing subgroup. Both halves…
Read article →ArticleTB-500 and Gut Research: The Counter-Evidence
Two published studies found thymosin beta 4 weakened the gut lining in rats and mice. Here is what they measured, what they did not…
Read article →ArticleTB-500 and Eye Research: The Deepest Human Dataset
The eye is where thymosin beta-4 has the most human data. A plain-language look at the dry eye trials, the p=0.0656 Phase III, and…
Read article →ArticleTB-500 Doses Used in Published Research
The published thymosin beta-4 study figures, the animal numbers, and the honest answer for TB-500 itself: no human dose has ever been published.
Read article →ArticleReading a TB-500 Certificate of Analysis
What a TB-500 certificate of analysis should show, which identity numbers it must match, and why a 2023 peer-reviewed paper says batch testing matters.
Read article →ArticleTB-500 Brain Research: The One Study That Used It
One published animal study gave TB-500 itself and measured brain outcomes. Here is what it reported, the result it did not find, and what…
Read article →ArticleBPC-157 Doses Used in Published Research
What amounts has BPC-157 research actually used? The published animal figures, the human-tissue concentrations, and the honest answer on human dosing: none is published.
Read article →ArticleWhat Is BPC-157 Studied For? A Plain Guide
BPC-157 is studied in animal, cell, and tissue models of tendon, gut, blood vessel, nerve, and wound repair. A plain-language map of every research…
Read article →ArticleBPC-157 and Wound Healing: What Studies Report
A plain-language review of published BPC-157 wound research: a burn model, fistula repair in rats, and growth-factor comparisons. Animal and lab data only.
Read article →ArticleIs BPC-157 Banned for Athletes? WADA Status
BPC-157 is on the WADA Prohibited List in Section S2, prohibited at all times for tested athletes. What that means, and why the source…
Read article →ArticleBPC-157 vs KPV: How the Research Differs
BPC-157 and KPV are studied for different things, and both appear in gut research. A plain-language look at what the published work covers and…
Read article →ArticleBPC-157 vs GHK-Cu: How Their Research Differs
A plain-language comparison of BPC-157 and GHK-Cu: structure, size, the pathways each is studied through, the research areas each belongs to, and what neither…
Read article →ArticleBPC-157 and Tendons: What the Research Shows
A plain-language look at what published BPC-157 tendon studies actually report, which of them used cells or animals, and what the research still does…
Read article →ArticleWhy BPC-157 Is Stable: Triple-Proline and Storage
Why BPC-157 resists enzyme breakdown, what the gastric-juice stability report actually says, and how the lyophilized powder is stored in a research lab.
Read article →ArticleBPC-157 Sequence and Molecular Identity Explained
What BPC-157 actually is chemically: its 15-amino-acid sequence, molecular formula, weight, CAS number, aliases, and how lab testing confirms identity.
Read article →ArticleBPC-157 Safety Research: What Studies Report
What the published record actually reports about BPC-157 safety: no Phase II or III human efficacy trial, small pilot infusion references, and open questions.
Read article →ArticleIs BPC-157 FDA Approved? Regulatory Status Explained
BPC-157 is not an FDA-approved drug. What that means, the 2023-2026 compounding timeline, and how "approved," "scheduled," and "compounding list" differ.
Read article →ArticleHow BPC-157 Purity Is Tested and What ≥99% Means
BPC-157 purity is measured by reverse-phase HPLC. Learn what a ≥99% result means, what the other 1% is, and why lot-specific independent COAs matter.
Read article →ArticleBPC-157 and Pain: What the Research Says
What published research says about BPC-157 and pain: a 2026 review of pain-signal mechanisms, the animal-model context, and the limits of the evidence.
Read article →ArticleBPC-157 Muscle Research: What Animal Studies Show
What published research says about BPC-157 and muscle: a 2022 review across three muscle types, 2025 rat reattachment models, and what the animal evidence…
Read article →ArticleBPC-157 Ligament Research: What Animal Studies Show
What published research says about BPC-157 and ligaments: the 2010 rat MCL study, a 2026 mechanism review, and what the animal evidence does and…
Read article →ArticleAre There Human Trials of BPC-157? The Honest Answer
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is…
Read article →ArticleBPC-157 Heart Research: What Animal Studies Show
A plain-language look at what published animal research has studied about BPC-157 and the heart: bleeding, clotting, heart rhythm, and the aortic wall.
Read article →ArticleBPC-157 Gut Research: What the Animal Studies Show
BPC-157 comes from a protein in human gastric juice. Plain-language look at the rat and tissue studies on the digestive tract, and what they…
Read article →ArticleBPC-157 and the Eye: What Animal Research Shows
Published eye research on BPC-157 rests mainly on one 2023 review of glaucoma and other animal models. Here is what it covers, and what…
Read article →ArticleHow to Read a BPC-157 Certificate of Analysis
A field-by-field walkthrough of a BPC-157 COA: the exact sequence, molecular weight, purity value, CAS number, and lot details a researcher should check.
Read article →ArticleBPC-157 Brain and Nervous System Research
What published research says about BPC-157 and the brain: one 2021 animal-model review, a 2026 pain-pathway review, and an honest look at how thin…
Read article →ArticleBPC-157 and Blood Vessels: What the Research Says
A plain-language look at published BPC-157 blood vessel research, including the 2026 human artery tissue study, what ex vivo means, and what the studies…
Read article →ArticleBPC-157 Alone vs. Blends: What Actually Differs
How standalone BPC-157 differs from the pre-mixed blends that contain it, what is in each vial, and why combining peptides is a research idea,…
Read article →ArticleBPC-157 in 2026: Preclinical Foundation Meets Human-Tissue Evidence
BPC-157 2026 research review — Yildirim ex-vivo human mammary artery vasorelaxation, the 2010-2023 mechanism foundation (Cerovecki, Chang FAK-paxillin, Sikiric), and honest counter-evidence.
Read article →ArticleBPC-157 vs TB-500: Tissue Repair Comparison 2026
What published research actually says about BPC-157 and TB-500 — sequences, study models, human-evidence gaps, and why no combination study exists.
Read article →ArticleBPC-157, TB-500, KPV, GHK-Cu: Mechanisms Across the Tissue-Repair Cascade
What published research says about BPC-157, TB-500, KPV and GHK-Cu: the models each has been studied in, where the human evidence stops, and why…
Read article →Related Products
Tissue-Repair Research
What question does this field ask?
Not "does it heal", but which step of repair changed and by how much. Repair runs in stages: stopping bleeding, clearing damage, laying down new matrix, growing vessels, and remodeling. A study picks one stage, one tissue and one model, and measures it. That is why a single paper on tendon cells says nothing about gut lining, and why the articles here are organized by model, not by compound.
Which compounds appear, and why?
BPC-157, TB-500 and KPV, plus the blends built from them. BPC-157 is the most-studied, mainly in rat tendon, ligament and GI models, with a 2026 ex-vivo human artery study. TB-500 carries the actin-binding domain of thymosin β4, and its literature includes a 2025 report of the parent protein impairing the intestinal barrier in a stress model. KPV is read in inflammation-pathway and colitis models, often delivered in engineered hydrogels.
What do the studies measure?
Cell migration speed, collagen alignment, vessel density, barrier integrity and pathway markers such as FAK, paxillin and VEGFR2. Almost none of it is human: the 2026 artery-ring study used donated human vessel tissue ex vivo, which is as close as the record gets. Each article below names its model in the first paragraph, and each product page reports the findings that cut against the compound next to the ones in its favor.
How do the compounds compare?
| Compound | What it is | Sequence / formula | Molecular weight | Sources cited on its page |
|---|---|---|---|---|
| BPC-157 | 15-amino-acid synthetic peptide | GEPPPGKPADDAGLV | 1,419.5 g/mol | 27 |
| TB-500 | 7-residue N-acetylated fragment of thymosin β4 (residues 17–23) | Ac-LKKTETQ | 889.0 g/mol | 25 |
| KPV | α-MSH C-terminal tripeptide (residues 11–13) | Lys-Pro-Val | 342.4 g/mol | 7 |
| GHK-Cu | copper(II) complex of the tripeptide GHK | Gly-His-Lys · Cu²⁺ | 340.4 g/mol (free tripeptide) | 11 |
| GLOW | three-component blend: GHK-Cu, BPC-157, TB-500 | see each component | per component | 23 |
| KLOW | four-component blend: KPV, GHK-Cu, BPC-157, TB-500 | see each component | per component | 9 |
Sequences and molecular weights are the values verified on each product page. "Sources cited" is the count shown on that page on 28 August 2026.
Where do I read more?
Every compound on this page is supplied for laboratory research only. Each product page carries its full reference list.
References
- Yuan C et al. (2026). From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. PMID 41898733
- Philp D et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db mice. Wound Repair Regen. PMID 12581423
- Sun Y et al. (2025). Thymosin β4 released by mast cells under stress conditions impairs intestinal epithelial barrier. World J Gastroenterol. PMID 41278163
- Jeong H et al. (2025). Multicompartmental hydrogel microspheres protecting and targeting KPV to colonic epithelium. ACS Appl Bio Mater. PMID 40030207